Oncology
Commented by Matthias Schomber on July 15th, 2026 | 08:45 CEST
AI, Oncology, and Defense: TeamViewer, BioNTech, and Antimony Resources—A Great Mix for Your Portfolio!
Created and published on behalf of Antimony Resources Corp.
The stock market is a place of extremes, and today we are looking at a trio—TeamViewer, BioNTech, and Antimony Resources—that comes from three different sectors. There is a German software pioneer that, after painful setbacks, is suddenly showing clear signs of life again. There is a once-celebrated vaccine hero pumping billions into a risky but revolutionary future in cancer therapy—while still holding a substantial cash reserve. And then there is a Canadian mineral explorer digging deep into the earth for a material without which our modern world would simply grind to a halt—one that is also crucial for the defense industry. It is precisely this mix of a software-AI turnaround, a biotech-oncology transformation, and mineral potential that makes the market so incredibly exciting. Join us on a journey through three fascinating corporate stories.
Read
Commented by Armin Schulz on September 10th, 2025 | 07:05 CEST
Oncology boom: How Bayer, Vidac Pharma, and BioNTech could outperform with their full pipelines
The oncology industry is facing an unprecedented wave of growth: the global market is expected to double to over USD 866 billion by 2034. Driven by demographic factors, groundbreaking immunotherapies, and a record number of new drugs, investors are facing a historic window of opportunity. Those who invest in the right innovators with bulging pipelines and disruptive technologies can benefit from this mega-trend wave. This is precisely where the promising strategies of Bayer, Vidac Pharma, and BioNTech come in.
Read
Commented by Armin Schulz on August 7th, 2025 | 07:15 CEST
New Tariff Drama – How Novo Nordisk, Vidac Pharma, and BioNTech are using AI and oncology to counter protectionism
The global pharmaceutical industry is experiencing a historic double revolution in 2025: Artificial Intelligence is accelerating research and personalized therapies, while disruptive US tariffs of up to 250% are reshaping supply chains. These forces are colliding as innovation meets protectionism. The winners are mastering both. They are leveraging digital breakthroughs and circumventing trade barriers through strategic production relocation. Those who invest now stand to benefit from the race to shape the future of global healthcare markets. The area with the most promising growth is oncology. We take a closer look at three exciting companies from the pharmaceutical and biotech industries: Novo Nordisk, Vidac Pharma, and BioNTech.
Read
Commented by Armin Schulz on June 2nd, 2025 | 07:10 CEST
Bayer, Vidac Pharma, Evotec – Grab your share of the USD 866 billion oncology jackpot
Oncology is undergoing an unprecedented revolution. With a projected market volume of USD 866 billion by 2034 and annual growth of 11%, AI-driven diagnostics, personalized gene therapies, and precision medicine are driving this boom. Rising disease rates worldwide are fueling investment, while technological leaps are making therapies more effective and opening up high-return opportunities. Three players aim to leverage this explosive momentum for their profitable future: Bayer, Vidac Pharma, and Evotec.
Read